PCSK9 and atherosclerosis: Proprotein convertase subtilisin kexin 9 (PCSK9) that regulates the levels of the LDL receptor [53] has attracted the interest in research in the field of lipidology not only as target for treatment (PCSK9 inhibitors) but also as a marker for atherosclerosis [54,55].